Pharsight

1. List of Zurampic drug patents

Application	Filing Date	Opposition Party	Legal Status
EP11796324A	2018-12-21	Hexal AG	Revoked
EP11796324A	2018-12-21	Bülle Dr., Jan	Revoked
EP11796324A	2018-12-20	Alfred E. Tiefenbacher (GmbH & Co. KG)	Revoked
EP11853861A	2017-09-14	Alfred E. Tiefenbacher (GmbH & Co. KG)	Opposition rejected
EP11853861A	2017-09-14	STADA Arzneimittel AG	Opposition rejected

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8003681	IRONWOOD PHARMS INC	2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and methyl ester	Aug, 2025 (2 years from now)
US8546436	IRONWOOD PHARMS INC	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Feb, 2032 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8283369	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Nov, 2028 (5 years from now)
US10183012	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Nov, 2028 (5 years from now)
US8546437	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Apr, 2029 (5 years from now)
US8084483	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Aug, 2029 (6 years from now)
US8357713	IRONWOOD PHARMS INC	Compounds and compositions and methods of use	Dec, 2029 (6 years from now)
US9216179	IRONWOOD PHARMS INC	Treatment of gout and hyperuricemia	Aug, 2031 (8 years from now)
US9956205	IRONWOOD PHARMS INC	Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid and uses thereof	Dec, 2031 (8 years from now)

Do you want to check out ZURAMPIC patents from before 2022?

Market Authorisation Date: 22 December, 2015

Treatment: Achieving a therapeutic benefit in a subject with gout; Treatment of gout; Treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthi...

Dosage: TABLET;ORAL